Published in Arthritis Rheum on July 01, 2004
Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther (2005) 2.69
Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis (2005) 2.35
Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med (2008) 2.17
The HLA-DRB1 shared epitope is associated with susceptibility to rheumatoid arthritis in African Americans through European genetic admixture. Arthritis Rheum (2008) 2.13
Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A (2011) 2.07
Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther (2005) 2.03
A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J Exp Med (2013) 1.69
Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study. Ann Rheum Dis (2007) 1.49
Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis Rheum (2008) 1.48
Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis. Arthritis Res Ther (2006) 1.40
Rheumatoid arthritis: a view of the current genetic landscape. Genes Immun (2008) 1.32
The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now? Arthritis Res Ther (2008) 1.30
Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis. Arthritis Res Ther (2006) 1.27
HLA-DR1001 presents "altered-self" peptides derived from joint-associated proteins by accepting citrulline in three of its binding pockets. Arthritis Rheum (2010) 1.27
Genetics of rheumatoid arthritis: what have we learned? Immunogenetics (2011) 1.21
Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol (2006) 1.18
Cells of the synovium in rheumatoid arthritis. Dendritic cells. Arthritis Res Ther (2007) 1.16
Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies. QJM (2009) 1.13
Consumption of water containing a high concentration of molecular hydrogen reduces oxidative stress and disease activity in patients with rheumatoid arthritis: an open-label pilot study. Med Gas Res (2012) 1.10
Shared epitope alleles remain a risk factor for anti-citrullinated proteins antibody (ACPA)--positive rheumatoid arthritis in three Asian ethnic groups. PLoS One (2011) 1.09
Ethnogenetic heterogeneity of rheumatoid arthritis-implications for pathogenesis. Nat Rev Rheumatol (2010) 1.09
CTLA4 is differentially associated with autoimmune diseases in the Dutch population. Hum Genet (2005) 1.06
Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther (2005) 1.03
T-cell autoreactivity to citrullinated autoantigenic peptides in rheumatoid arthritis patients carrying HLA-DRB1 shared epitope alleles. Arthritis Res Ther (2012) 1.03
A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm. Rheumatology (Oxford) (2011) 0.97
Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis in early undifferentiated arthritis. Clin Rheumatol (2007) 0.95
A principal-components-based clustering method to identify multiple variants associated with rheumatoid arthritis and arthritis-related autoantibodies. BMC Proc (2009) 0.94
Opposing effects of the D70 mutation and the shared epitope in HLA-DR4 on disease activity and certain disease phenotypes in rheumatoid arthritis. Ann Rheum Dis (2007) 0.94
Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis. Clin Rheumatol (2008) 0.94
Diagnostic value of anti-cyclic citrullinated peptide antibodies in northern Chinese Han patients with rheumatoid arthritis and its correlation with disease activity. Clin Rheumatol (2010) 0.90
Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis. BMC Musculoskelet Disord (2007) 0.89
Genome-wide association study of determinants of anti-cyclic citrullinated peptide antibody titer in adults with rheumatoid arthritis. Mol Med (2009) 0.88
Dendritic cells and the promise of antigen-specific therapy in rheumatoid arthritis. Arthritis Res Ther (2013) 0.88
Anti-citrullinated fibronectin antibodies in rheumatoid arthritis are associated with human leukocyte antigen-DRB1 shared epitope alleles. Arthritis Res Ther (2012) 0.87
A chronic model of arthritis supported by a strain-specific periarticular lymph node in BALB/c mice. Nat Commun (2013) 0.86
Prediction models for rheumatoid arthritis during diagnostic investigation: evaluation of combinations of rheumatoid factor, anti-citrullinated protein/peptide antibodies and the human leucocyte antigen-shared epitope. Ann Rheum Dis (2006) 0.86
Association between ankylosing spondylitis and the miR-146a and miR-499 polymorphisms. PLoS One (2015) 0.85
The association of anti-CCP antibodies with disease activity in rheumatoid arthritis. Rheumatol Int (2008) 0.85
The relationship between the presence of anti-cyclic citrullinated peptide antibodies and clinical phenotype in very early rheumatoid arthritis. BMC Musculoskelet Disord (2010) 0.85
A transmembrane polymorphism in FcgammaRIIb (FCGR2B) is associated with the production of anti-cyclic citrullinated peptide autoantibodies in Taiwanese RA. Genes Immun (2008) 0.84
Association study of human leukocyte antigen-DRB1 alleles with rheumatoid arthritis in south Tunisian patients. Clin Rheumatol (2012) 0.83
Contribution of HLA-DRB1*04 alleles and anti-cyclic citrullinated antibodies to development of resistance to disease-modifying antirheumatic drugs in early rheumatoid arthritis. Clin Rheumatol (2010) 0.82
Prognostic factors of radiographic progression in early rheumatoid arthritis: a two year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids. Clin Rheumatol (2006) 0.82
The influence of polygenic risk scores on heritability of anti-CCP level in RA. Genes Immun (2014) 0.81
A new classification of HLA-DRB1 alleles differentiates predisposing and protective alleles for autoantibody production in rheumatoid arthritis. Arthritis Res Ther (2007) 0.81
Anti-citrullinated glucose-6-phosphate isomerase peptide antibodies in patients with rheumatoid arthritis are associated with HLA-DRB1 shared epitope alleles and disease activity. Clin Exp Immunol (2013) 0.80
Decreased severity of experimental autoimmune arthritis in peptidylarginine deiminase type 4 knockout mice. BMC Musculoskelet Disord (2016) 0.80
[Autoantibody profile in rheumatoid arthritis]. Z Rheumatol (2007) 0.79
Association of cross-reactive antibodies targeting peptidyl-arginine deiminase 3 and 4 with rheumatoid arthritis-associated interstitial lung disease. PLoS One (2014) 0.79
HLA-DRB1 and HLA-DQB1 allele associations in an Albanian patient population with rheumatoid arthritis: correlations with the specific autoantibody markers and inter-population DRB1 allele frequency variability. Rheumatol Int (2014) 0.79
RADB: a database of rheumatoid arthritis-related polymorphisms. Database (Oxford) (2014) 0.78
Influence of human leucocyte antigen-DRB1 on the susceptibility to rheumatoid arthritis and on the production of anti-cyclic citrullinated peptide antibodies in a Portuguese population. Ann Rheum Dis (2006) 0.78
HLA-DR/DQ Genotypes in Kurd Patients with Rheumatoid Arthritis: Relation to Disease Activity. J Clin Diagn Res (2014) 0.78
A study on FoxP3 and Tregs in paired samples of peripheral blood and synovium in rheumatoid arthritis. Cent Eur J Immunol (2016) 0.77
Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies. Pharmgenomics Pers Med (2010) 0.77
Osteoprotegerin CGA haplotype protection against cerebrovascular complications in anti-CCP negative patients with rheumatoid arthritis. PLoS One (2014) 0.77
Assessment of peripheral neuropathy in patients with rheumatoid arthritis who complain of neurologic symptoms. Ann Rehabil Med (2014) 0.77
Genetic studies of rheumatoid arthritis. Proc Jpn Acad Ser B Phys Biol Sci (2015) 0.77
PADI4 haplotypes in association with RA Mexican patients, a new prospect for antigen modulation. Clin Dev Immunol (2013) 0.76
Rheumatoid arthritis. Evidence for a genetic component to disease severity in RA. Nat Rev Rheumatol (2012) 0.76
A candidate gene study of CLEC16A does not provide evidence of association with risk for anti-CCP-positive rheumatoid arthritis. Genes Immun (2010) 0.75
Antibodies against cyclic citrullinated peptide don't decrease after 6 months of infliximab treatment in refractory rheumatoid arthritis. Rheumatol Int (2010) 0.75
The Mechanisms Underlying Chronic Inflammation in Rheumatoid Arthritis from the Perspective of the Epigenetic Landscape. J Immunol Res (2016) 0.75
The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases. Biomark Insights (2007) 0.75
Cytotoxic T cells modulate inflammation and endogenous opioid analgesia in chronic arthritis. J Neuroinflammation (2017) 0.75
Reduced TCR-dependent activation through citrullination of a T-cell epitope enhances Th17 development by disruption of the STAT3/5 balance. Eur J Immunol (2016) 0.75
Human Leukocyte Antigen-Disease Associations in Rheumatoid Arthritis. Rheum Dis Clin North Am (2017) 0.75
[Austrian expert opinion on the standard for expert assessment of course of illness in patients with chronic polyarthritis (rheumatoid arthritis)]. Wien Klin Wochenschr (2008) 0.75
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum (2010) 18.82
2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis (2010) 12.12
Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis (2010) 10.97
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis (2013) 10.92
Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum (2003) 10.65
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis (2010) 10.03
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet (2010) 9.90
Rheumatoid arthritis. Lancet (2010) 9.37
Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet (2008) 7.07
Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol (2007) 6.92
How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum (2002) 5.33
Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum (2005) 5.18
Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med (2007) 5.05
PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays (2003) 5.04
Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med (2002) 4.54
High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet (2012) 4.46
Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. PLoS Genet (2011) 3.68
Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum (2007) 3.66
Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans. Hum Immunol (2005) 3.65
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum (2009) 3.58
Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet (2009) 3.52
A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis. PLoS Med (2007) 3.41
A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum (2007) 3.23
Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum (2010) 3.08
Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum (2003) 3.05
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis (2010) 2.91
Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum (2008) 2.83
Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther (2005) 2.69
CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum (2003) 2.68
Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J Biol Chem (2003) 2.63
Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther (2004) 2.58
Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum (2006) 2.56
The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum (2006) 2.46
A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum (2007) 2.36
Association of the interleukin-1 gene cluster with radiographic signs of osteoarthritis of the hip. Arthritis Rheum (2004) 2.33
Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells. Arthritis Rheum (2005) 2.32
Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum (2005) 2.30
Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum (2010) 2.27
Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Rheum (2009) 2.24
Antibodies to porphyromonas gingivalis are associated with anticitrullinated protein antibodies in patients with rheumatoid arthritis and their relatives. J Rheumatol (2010) 2.21
Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res (2001) 2.18
In erosive hand osteoarthritis more inflammatory signs on ultrasound are found than in the rest of hand osteoarthritis. Ann Rheum Dis (2012) 2.17
The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum (2004) 2.12
Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum (2010) 2.08
Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A (2011) 2.07
Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis. Arthritis Res Ther (2004) 2.05
Prospective study of clinical phenotypes in neuropsychiatric systemic lupus erythematosus; multidisciplinary approach to diagnosis and therapy. J Rheumatol (2012) 2.04
Do knee abnormalities visualised on MRI explain knee pain in knee osteoarthritis? A systematic review. Ann Rheum Dis (2010) 2.01
Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum (2006) 2.00
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum (2010) 1.94
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2011) 1.93
Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging. Arthritis Rheum (2002) 1.92
Is a long-term high-intensity exercise program effective and safe in patients with rheumatoid arthritis? Results of a randomized controlled trial. Arthritis Rheum (2003) 1.92
Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis Rheum (2003) 1.88
Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype. Arthritis Rheum (2008) 1.86
Quantitative heritability of anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis. Arthritis Rheum (2009) 1.80
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis (2012) 1.78
Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum (2010) 1.77
Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis (2007) 1.77
Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum (2009) 1.75
Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. Arthritis Rheum (2007) 1.72
Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis. Ann Rheum Dis (2012) 1.68
Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism. Arthritis Rheum (2002) 1.67
Retracted Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium. Arthritis Res Ther (2011) 1.65
Association between weight or body mass index and hand osteoarthritis: a systematic review. Ann Rheum Dis (2009) 1.63
Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis (2006) 1.62
Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Ann Rheum Dis (2011) 1.62
Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets. Arthritis Res Ther (2008) 1.61
Rituximab in relapsing Graves' disease, a phase II study. Eur J Endocrinol (2008) 1.59
Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis (2010) 1.59
Predicting arthritis outcomes--what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford) (2010) 1.58